AstraZeneca and one of its key European suppliers have defended the quality of their Covid-19 vaccine production process after the EU drugs regulator said it was investigating whether there could have been manufacturing defects in specific batches.
阿斯利康(AstraZeneca)及其主要欧洲供应商之一为其新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）疫苗生产过程的质量辩护。此前欧盟药品监管机构称其正在调查特定批次的疫苗是否存在制造缺陷。
您已阅读6%（351字），剩余94%（5623字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。